Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
EHRA 2019: Internal vs. External Electrical Cardioversion of Atrail Arrhythmias in Patients With an Implantable Cardioverter-Defibrillator (ICD)
Author(s): Jakob Luker Added: 5 years ago
Dr Jakob Lüker (University Hospital Cologne, DE) discusses internal vs. external electrical cardioversion of atrail arrhythmias in patients with an implantable cardioverter-defibrillator (ICD). Filmed on site by Radcliffe Cardiology. Questions: 1. What is the concern with atrial conversions in patients with AICDs (automated implantable cardioverter defibrillator)? (00:10) 2. How does… View more

Electrophysiology & Arrhythmia
Job title: Cardiologist
Dr Bruce Wilkoff is the Director of Cardiac Pacing and Tachyarrhythmia Devices and a staff cardiologist at Cleveland Clinic Main Campus, Cleveland, US. Dr Wilkoff is also a Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. He is board-certified in internal medicine, cardiovascular disease and a Certified Cardiac Device Specialist. His… View more
OD THUMB
Author(s): Cecilia Linde , Wilfried Mullens , Michael R Gold Start date: Mar 23, 2021

Electrophysiology & Arrhythmia
Job title: Professor
Prof Paul Kalra is Professor of Cardiologyat Portsmouth Hospitals NHS Trust, UK.The majority of his work involves assessment, investigation and management of patients with known or suspected cardiac problems. While he has a broad interest in all aspects of general adult cardiology, his sub-specialty interest is the assessment and management of patients with heart failure. Prof Kalra has… View more
The IRONMAN Trial
Author(s): Paul Kalra Added: 1 year ago
Iron deficiency is common in heart failure, particularly in hospitalised patients and may exacerbate symptoms and increase the risk of hospitalisation and premature mortality. Although previous studies have shown that intravenous iron provides improvement in exercise capacity and reduces hospitalisation in patients with HF and iron deficiency, longer term efficacy and safety data has been lacking… View more

Heart Failure

Prevention & Chronic Conditions
Chagas Heart Failure in Patients from Latin America
Author(s): Reinaldo B Bestetti Added: 3 years ago
More than a century after its discovery, Chagas disease still is a major health problem in Latin America, with 5.7 million people in 21 countries being affected by it.1 Moreover, about 70 million people are at risk of acquiring the illness.1 Cases of Chagas disease are now found globally; there are more than 400,000 immigrants with this disease living in Europe (mainly in Spain, Italy and France)… View more

Vascular Disease and Surgery

Heart Failure
Long-Term Survival Benefit Associated with CRT-D Compared to ICD in HF in the RAFT Trial
Added: 2 months ago Source:  Radcliffe Cardiology, Jordan Rance; Special Editor: Greg Guillory
RAFT, a new extended follow-up trial (NCT00251251) showed insight into the survival benefit associated with coronary resynchronization therapy defibrillator (CRT-D) as compared to implantable cardioverter-defibrillator (ICD) in patients with heart failure.Methodology:The Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) is a randomized trial which aimed to compare the… View more
Author(s): Robert D Adam , James Shambrook , Andrew S Flett Added: 3 years ago
The current lifetime risk of heart failure is approximately one in three and the prognosis remains poor.1 The latest UK heart failure audit data reveal inpatient and 1-year mortality rates of 10% and 27%, respectively.2 The aetiology of heart failure is diverse, and many patients have several cardiac and non-cardiac pathologies that conspire to cause the syndrome. Currently the most common cause… View more

Heart Failure
Author(s): Lampros Papadimitriou , Charles K Moore , Javed Butler , et al Added: 4 years ago
Heart failure (HF) is a global epidemic which affects about 6 million adults in the US. It is projected that by 2030 the total cost of HF will reach US$70 billion. Despite the development of novel drugs and devices, the mortality burden of HF remains high, with one in three patients dying within 1 year of hospitalisation for HF and 40–50% within 5 years of diagnosis.1 Patients with HF are… View more

Standards & Guidelines

Heart Failure